FDA approves mRNA flu vaccine mFlusiva amid regulatory challenges

In April 2024, the U.S. Food and Drug Administration (FDA) approved a new mRNA-based vaccine for influenza, named mFlusiva, developed by Moderna. This approval came after a complex and somewhat contentious review process, which highlighted the ongoing debates surrounding mRNA technology in the vaccine landscape. Jeff Coller, a distinguished professor at Johns Hopkins University, noted that while the approval does not indicate a shift in the administration's overall stance on mRNA, it does reflect that the FDA's approval process remains functional despite existing anti-mRNA sentiments.

The approval process for mFlusiva was described as 'tortured' by Dr. Paul Offit, director of the Vaccine Education Center at Children's Hospital of Philadelphia. Before initiating its final trial, Moderna sought feedback from the FDA regarding the trial's design, which the FDA approved. However, when Moderna later submitted data for approval, there was a brief period of uncertainty as a new official at the FDA's Center for Biologics Evaluation and Research (CBER) initially rejected the application, despite no changes in the evidence presented. Eventually, the FDA's vaccine advisory committee, known as the Vaccines and Related Biological Products Advisory Committee (VRBPAC), convened to evaluate the vaccine's safety and effectiveness, leading to its eventual approval.

Following the FDA's approval, the next step involves the Centers for Disease Control and Prevention (CDC) reviewing the data to provide recommendations on the vaccine's administration. However, the process is complicated by ongoing legal issues affecting the Advisory Committee on Immunization Practices (ACIP), which has recently faced a federal judge's ruling that has frozen several changes within the committee. Despite these challenges, the approval of mFlusiva means it can be utilized without specific CDC recommendations, which is significant as the upcoming flu season approaches.

The mRNA flu vaccine is expected to offer advantages over traditional flu shots, including faster production times and better adaptability to match circulating flu strains. Initial trials suggest that mFlusiva may provide enhanced protection, particularly for adults aged 50 to 64, and further data will be collected to assess its effectiveness in older adults over 64. The approval of mFlusiva indicates that regulatory bodies in the U.S. are still capable of reviewing and approving new mRNA vaccine products, suggesting a potential future for mRNA technology in the vaccine market.